Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA.
Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.
Mod Pathol. 2014 Mar;27(3):420-32. doi: 10.1038/modpathol.2013.148. Epub 2013 Sep 20.
The majority of hepatocellular carcinomas arise in background chronic liver disease, particularly cirrhosis. The pathogenesis of noncirrhotic hepatocellular carcinomas remains unclear. While malignant transformation reportedly occurs in <15% of hepatocellular adenoma, the prevalence of noncirrhotic hepatocellular carcinomas arising from a pre-existing adenoma is a challenge to study. Cirrhotic hepatocellular carcinoma and hepatocellular adenoma may be subclassified by molecular pathways, but little is known in noncirrhotic hepatocellular carcinoma. We aim to delineate clinical, morphologic and immunohistochemical features of noncirrhotic hepatocellular carcinoma to evaluate for possible derivation from hepatocellular adenoma. We evaluated the clinicopathologic features of 74 noncirrhotic hepatocellular carcinomas from 72 patients for underlying clinical conditions and immunohistochemical markers known to be associated with hepatocellular adenoma. Men were more commonly affected (59%); however, in the <50-year-old group, women predominated (8:1). The age range was wide: 18-83 years; median-64 years. Underlying liver diseases were identified in only 7%; however, 25% had diabetes mellitus, 69% were overweight or obese and 58% had metabolic syndrome. Only 50% of the noncirrhotic hepatocellular carcinoma were encapsulated. As published in hepatocellular adenoma, multifocality and larger tumor size were more common in liver fatty acid-binding protein-negative noncirrhotic hepatocellular carcinoma. Beta-catenin nuclear positivity was uncommon (5%), and was restricted to hepatocellular carcinomas in older men. Serum amyloid A positivity was not restricted to any subtype. In summary, we present the largest series to date examining noncirrhotic hepatocellular carcinoma. We evaluated these with current hepatocellular adenoma subclassification markers for possible associations. Thirty percent of the 74 noncirrhotic hepatocellular carcinoma had some clinical, morphological or immunophenotypical associations currently described in hepatocellular adenoma. Our data also confirm the association of noncirrhotic hepatocellular carcinoma in middle-aged to elderly men, an association with metabolic syndrome, and, as with hepatocellular adenoma, that women predominated in the noncirrhotic hepatocellular carcinoma subjects <50 years of age.
大多数肝细胞癌发生在慢性肝病背景下,尤其是肝硬化。非肝硬化性肝细胞癌的发病机制仍不清楚。虽然据报道肝细胞腺瘤中恶性转化发生率<15%,但从先前存在的腺瘤中发生非肝硬化性肝细胞癌的患病率是一个具有挑战性的研究课题。肝硬化性肝细胞癌和肝细胞腺瘤可通过分子途径进行分类,但在非肝硬化性肝细胞癌中知之甚少。我们旨在描绘非肝硬化性肝细胞癌的临床、形态学和免疫组织化学特征,以评估其是否可能来源于肝细胞腺瘤。我们评估了 72 例患者的 74 例非肝硬化性肝细胞癌的临床病理特征,以评估与肝细胞腺瘤相关的潜在临床情况和免疫组织化学标志物。男性更常见(59%);然而,在<50 岁的患者中,女性占主导地位(8:1)。年龄范围很广:18-83 岁;中位数-64 岁。仅在 7%的患者中确定了基础肝病;然而,25%患有糖尿病,69%超重或肥胖,58%患有代谢综合征。只有 50%的非肝硬化性肝细胞癌有包膜。如在肝细胞腺瘤中报道的那样,在肝脏脂肪酸结合蛋白阴性的非肝硬化性肝细胞癌中,多灶性和更大的肿瘤大小更为常见。贝塔连环蛋白核阳性并不常见(5%),仅限于老年男性的肝细胞癌。血清淀粉样蛋白 A 阳性不受任何亚型限制。总之,我们目前展示了迄今为止最大的非肝硬化性肝细胞癌系列研究。我们用目前的肝细胞腺瘤亚分类标志物评估这些标志物,以确定可能的关联。74 例非肝硬化性肝细胞癌中有 30%具有目前在肝细胞腺瘤中描述的某些临床、形态学或免疫表型关联。我们的数据还证实了非肝硬化性肝细胞癌在中年至老年男性中的关联,与代谢综合征的关联,以及与肝细胞腺瘤一样,在<50 岁的非肝硬化性肝细胞癌患者中女性占主导地位。